Virginia Governor to sign mandatory HPV vaccine bill

Share this article:
Virginia Governor Timothy Kaine told the Associated Press on Thursday that he would sign legislation requiring all sixth-grade girls to be vaccinated against human papillomavirus (HPV), the sexually transmitted virus that can cause cervical cancer. If Kaine does sign the bill, Virginia would become the second state, after Texas, to mandate the vaccine, and the first to do so through legislative action. Kaine, a Democrat, said he wanted to make sure a provision in the bill that allows parents to review information about the vaccine and exempt their daughters was generous enough “for a parent to opt out of this without having to jump through hoops.” If signed into law, the bill would not go into effect until October 2008, making the 2009 school year the first when girls would be required to receive the vaccine. Currently, Merck’s Gardasil is the only FDA approved HPV vaccine on the market. In early February, Texas Gov. Rick Perry, a Republican, signed an order making Texas the first state to require schoolgirls be vaccinated against HPV. Perry however sidestepped the legislature in ordering the vaccine for girls in that state and lawmakers there are considering overturning the order. Last month, Merck said it would stop lobbying states to pass laws requiring preteen girls be vaccinated against cervical cancer, following a growing backlash among parents, healthcare providers and consumer groups, Merck’s aggressive lobbying campaign was intended to bolster sales of Gardasil, which was approved last year. The vaccine provides protection against the two strains of HPV thought to cause a majority of cervical cancer cases.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...